• Je něco špatně v tomto záznamu ?

Early mortality critically impedes improvements in thyroid cancer survival through a half century

F. Tichanek, A. Försti, V. Liska, O. Hemminki, A. Koskinen, A. Hemminki, K. Hemminki

. 2023 ; 189 (3) : 355-362. [pub] 2023Sep01

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016299

Grantová podpora
856620 European Union's Horizon 2020 research and innovation program
Jane and Aatos Erkko Foundation
Sigrid Juselius Foundation
Finnish Cancer Organizations
University of Helsinki
Helsinki University Central Hospital
Novo Nordisk Foundation
Päivikki and Sakari Sohlberg Foundation
Finnish Red Cross Blood Service
Cooperatio Program, research area SURG
LX22NPO5102 National Institute for Cancer Research-NICR
European Union-Next Generation EU

OBJECTIVES: We analyze survival in thyroid cancer from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) over a 50-year period (1971-2020), and additionally consider concomitant changes in incidence and mortality. DESIGN: Population-based survival study. METHODS: Relative 1-, 5/1 (conditional)-, and 5-year survival data were obtained from the NORDCAN database for years 1971-2020. Incidence and mortality rates were also assessed. RESULTS: A novel consistent observation was that 1-year survival was worse than 5/1-year survival but the difference between these decreased with time. Relative 1-year survival in thyroid cancer (mean for the 4 countries) reached 92.7% for men and 95.6% for women; 5-year survival reached 88.0% for men and 93.7% for women. Survival increased most for DK which started at a low level and reached the best survival at the end. Male and female incidence rates for thyroid cancer increased 3- and 4-fold, respectively. In the same time, mortality halved for men and for women, it decreased by 2/3. CONCLUSIONS: We documented worse relative survival in the first year than in the 4 subsequent years, most likely because of rare anaplastic cancer. Overall survival in thyroid cancer patients increased in the Nordic countries in the course of 50 years; 5-year survival was close to 90% for men and close to 95% for women. Even though overdiagnosis may explain some of 5-year survival increase, it is unlikely to influence the substantial increase in 1-year survival. The unmet need is to increase 1-year survival by diagnosing and treating aggressive tumors before metastatic spread.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016299
003      
CZ-PrNML
005      
20231026110040.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ejendo/lvad117 $2 doi
035    __
$a (PubMed)37675794
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tichanek, Filip $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svobody 76, 30605 Pilsen, Czech Republic $u Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Early mortality critically impedes improvements in thyroid cancer survival through a half century / $c F. Tichanek, A. Försti, V. Liska, O. Hemminki, A. Koskinen, A. Hemminki, K. Hemminki
520    9_
$a OBJECTIVES: We analyze survival in thyroid cancer from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) over a 50-year period (1971-2020), and additionally consider concomitant changes in incidence and mortality. DESIGN: Population-based survival study. METHODS: Relative 1-, 5/1 (conditional)-, and 5-year survival data were obtained from the NORDCAN database for years 1971-2020. Incidence and mortality rates were also assessed. RESULTS: A novel consistent observation was that 1-year survival was worse than 5/1-year survival but the difference between these decreased with time. Relative 1-year survival in thyroid cancer (mean for the 4 countries) reached 92.7% for men and 95.6% for women; 5-year survival reached 88.0% for men and 93.7% for women. Survival increased most for DK which started at a low level and reached the best survival at the end. Male and female incidence rates for thyroid cancer increased 3- and 4-fold, respectively. In the same time, mortality halved for men and for women, it decreased by 2/3. CONCLUSIONS: We documented worse relative survival in the first year than in the 4 subsequent years, most likely because of rare anaplastic cancer. Overall survival in thyroid cancer patients increased in the Nordic countries in the course of 50 years; 5-year survival was close to 90% for men and close to 95% for women. Even though overdiagnosis may explain some of 5-year survival increase, it is unlikely to influence the substantial increase in 1-year survival. The unmet need is to increase 1-year survival by diagnosing and treating aggressive tumors before metastatic spread.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory štítné žlázy $x diagnóza $x epidemiologie $7 D013964
650    _2
$a databáze faktografické $7 D016208
651    _2
$a Finsko $x epidemiologie $7 D005387
651    _2
$a Norsko $x epidemiologie $7 D009664
655    _2
$a časopisecké články $7 D016428
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Liska, Vaclv $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svobody 76, 30605 Pilsen, Czech Republic $u Department of Surgery, University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland $u Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Koskinen, Anni $u Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svobody 76, 30605 Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00009634 $t European journal of endocrinology $x 1479-683X $g Roč. 189, č. 3 (2023), s. 355-362
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37675794 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110034 $b ABA008
999    __
$a ok $b bmc $g 2000050 $s 1202661
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 189 $c 3 $d 355-362 $e 2023Sep01 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
GRA    __
$a 856620 $p European Union's Horizon 2020 research and innovation program
GRA    __
$p Jane and Aatos Erkko Foundation
GRA    __
$p Sigrid Juselius Foundation
GRA    __
$p Finnish Cancer Organizations
GRA    __
$p University of Helsinki
GRA    __
$p Helsinki University Central Hospital
GRA    __
$p Novo Nordisk Foundation
GRA    __
$p Päivikki and Sakari Sohlberg Foundation
GRA    __
$p Finnish Red Cross Blood Service
GRA    __
$p Cooperatio Program, research area SURG
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research-NICR
GRA    __
$p European Union-Next Generation EU
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace